19 research outputs found
Kaplan-Meier survival curve for mortality in (A) patients with 24 h-residual urine volume ≥100 ml (P = 0.764 by log-rank test) and in (B) patients with 24 h-residual urine volume <100 ml (P = 0.005 by log-rank test).
<p>Kaplan-Meier survival curve for mortality in (A) patients with 24 h-residual urine volume ≥100 ml (P = 0.764 by log-rank test) and in (B) patients with 24 h-residual urine volume <100 ml (P = 0.005 by log-rank test).</p
Cox regression analysis of all-cause mortality.
<p><sup>a</sup>Adjusted for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and single-pool Kt/V.</p><p><sup>b</sup>Adjusted for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and weekly Kt/V.</p><p>HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; PD, peritoneal dialysis; ERI, erythropoietin resistance index; HR, hazard ratios; CI, confidence interval; P, P-value.</p><p>Cox regression analysis of all-cause mortality.</p
Hazard ratios for all-cause mortality by category of ESA responsiveness based on a combination of ESA dosage and hemoglobin level.
<p>Adjusted model included for age, gender, diabetes mellitus, previous cardiovascular disease history, duration of dialysis, serum level of iron, ferritin, albumin, intact PTH, hsCRP, total cholesterol and Kt/V.</p><p><sup>a</sup>Median value of ESA dose in hemodialysis patients</p><p><sup>b</sup>Median value of ESA dose in peritoneal dialysis patients.</p><p>ESA, erythropoiesis-stimulating agent; Hb, hemoglobin; N, number of patients; HD, hemodialysis; PD, peritoneal dialysis; HR, hazard ratios; CI, confidence interval; P, P-value.</p><p>Hazard ratios for all-cause mortality by category of ESA responsiveness based on a combination of ESA dosage and hemoglobin level.</p
Univariate and multivariate Cox regression analysis for infection-related mortality and hospitalization serum ALP tertile.
<p>Univariate and multivariate Cox regression analysis for infection-related mortality and hospitalization serum ALP tertile.</p
Multivariate Cox regression analysis of mortality in study populations.
<p>Multivariate Cox regression analysis of mortality in study populations.</p
Baseline characteristics of the study populations.
<p>Baseline characteristics of the study populations.</p
Clinical characteristics of the study population according to tertiles of ERI.
<p>Data are expressed as means ± SD, medians (interquartile range) or numbers (percentages), as appropriate.</p><p>ERI, erythropoietin resistance index; BP, blood pressure; CVD, cardiovascular diseases; CCI, Charlson co-morbidity index; Ccr, creatinine clearance; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; hsCRP, high sensitivity C-reactive protein; IV, intravenous; Kt/V: K, dialyzer clearance; t, time; V, volume of water a patient’s body contains; PD, peritoneal dialysis; PTH, parathyroid hormone; SGA, subject global assessment; TSAT, transferrin saturation.</p><p>Clinical characteristics of the study population according to tertiles of ERI.</p
Baseline characteristics of patients according to baseline serum ALP tertile.
<p>Baseline characteristics of patients according to baseline serum ALP tertile.</p
Kaplan-Meier plot of patient survival by tertiles of erythropoietin resistance index in (A) hemodialysis and (B) peritoneal dialysis patients.
<p>Kaplan-Meier plot of patient survival by tertiles of erythropoietin resistance index in (A) hemodialysis and (B) peritoneal dialysis patients.</p